More than 120 industry players are engaged in evaluating the potential of over 280 stem cell therapy products

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years. Further, recent studies suggest that mesenchymal stem cells mesenchymal stem cells can be effectively used to improve patients’ resistance to the SARS-CoV-2 virus induced pneumonia leading to speedy recovery.

Advertisements

 

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

 

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

  • Source of stem cell
  • Allogeneic
  • Autologous

 

  • Origin of stem cell
  • Adult
  • Embryonic

 

  • Type of stem cell
  • Hematopoietic
  • Mesenchymal
  • Progenitor
  • Others

 

  • Lineage of stem cell
  • Adipose Tissue
  • Bone Marrow
  • Cord Blood
  • Others

 

  • Route of Administration
  • Intraarticular
  • Intracoronary
  • Intramuscular
  • Intramyocardial
  • Intrathecal
  • Intravenous
  • Surgical Implantations
  • Others

 

  • Therapeutic Area
  • Autoimmune / Inflammatory Disorder
  • Cardiovascular Disorders
  • Metabolic Disorder
  • Musculoskeletal Disorders
  • Oncological Disorders
  • Neurological Disorders
  • Ophthalmic Disorders
  • Others

 

  • End Users
  • Ambulatory Surgery Centers
  • Hospitals
  • Specialty Clinics

 

  • Key Geographies
  • North America
  • Europe
  • Asia-Pacific and Rest of the World

 

The Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)), report features the following companies, which we identified to be key players in this domain:

  • Anterogen
  • Athersys
  • CHABiotech
  • Cytopeutics
  • Hope Biosciences
  • Japan Regenerative Medicine
  • Lineage Cell Therapeutics
  • Orchard Therapeutics
  • Osiris Therapeutics
  • Pluristem Therapeutics
  • Promithera Biosciences
  • Regenexx
  • Stempeutics Research
  • SCM Life Sciences
  • TICEBA

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction
  3. Market Landscape
  4. Company Profiles
  5. Key Therapeutic Areas
  6. Assessment of Relative Competition and Growth Opportunities
  7. Academic Grants Analysis
  8. Clinical Trail Analysis
  9. Stem Cell Manufacturing Market Landscape and KPIs for Evaluating Contract

Services Partners

  1. Stem Cell Therapy Developers and CMOs: Opportunity Assessment
  2. Key Commercialization Strategies

 

  1. Market Forecast
  2. Conclusion
  3. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com